In February 2016, the US Food and Drug Administration (FDA) sought advice from the National Academy of Medicine, now part of the National Academies, “to help… develop a regulatory framework for opioid review, approval, and monitoring that balances individual need for pain control with consideration of the broader public health consequences of abuse and misuse.”1(p1482)